Ferinject (Vifor/Luitpold) reduces need for ESAs in Chronic Kidney Disease patients with Iron Deficiency

The FIND-CKD study was the largest and longest study ever conducted in patients with non-dialysis-dependent Chronic Kidney Disease (ND-CKD) to assess the efficacy and long term safety of IV iron for the treatment of Iron Deficiency Anaemia (IDA). More than 600 patients from 20 countries were included in this 56-week trial.

Ferinject (ferric carboxymaltose) from Vifor Pharma, was compared to oral iron treatment and the study met its primary endpoint, demonstrating that the Vifor product, given at a starting dose of 1,000mg and subsequent dosing as required reduces the need for treatment with erythropoiesis-stimulating agents (ESAs) or blood transfusion) in this patient population. Detailed results will be submitted at the American Society of Nephrology meeting in Atlanta in November.